Yeng Ye

Dr. Yeng Ye


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2023 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
YXYing Xu
Ying Xu
ZLZhuo Li
Zhuo Li
YYYi Yang
Yi Yang
LLLu Li
Lu Li
YZYanzhao Zhou
Yanzhao Zhou
XZXinming Zhao
Xinming Zhao
Purpose: To predict the tertiary lymphoid structures (TLSs) status and recurrence-free survival (RFS) of intrahepatic cholangiocarcinoma (ICC) patients using preoperative CT radiomics. Patients and methods: A total of 116 ICC patients were included (training: 86; external validation: 30). The enhanced CT images were performed for the radiomics model. The logistic regression analysis was applied for the clinical model. The combined model was based on the clinical and radiomics models. Results: A total of 107 radiomics features were extracted, and after being eliminated and selected, six features were combined to establish a radiomics model for TLSs prediction. Arterial phase diffuse hyperenhancement and AJCC 8th stage were combined to construct a clinical model. The combined (radiomics nomogram) model outperformed both the independent radiomics model and clinical model in the training cohort (AUC, 0.85 vs. 0.82 and 0.75, respectively) and was validated in the external validation cohort (AUC, 0.88 vs. 0.86 and 0.71, respectively). Patients in the rad-score no less than −0.76 (low-risk) group showed significantly better RFS than those in the less than −0.76 (high-risk) group (p < 0.001, C-index = 0.678). Patients in the nomogram score no less than −1.16 (low-risk) group showed significantly better RFS than those of the less than −1.16 (high-risk) group (p < 0.001, C-index = 0.723). Conclusions: CT radiomics nomogram could serve as a preoperative biomarker of intra-tumoral TLSs status, better than independent radiomics or clinical models; preoperative CT radiomics nomogram achieved accurate stratification for RFS of ICC patients, better than the postoperative pathologic TLSs status. Critical relevance statement: The radiomics nomogram showed better performance in predicting TLSs than independent radiomics or clinical models and better prognosis stratification than postoperative pathologic TLSs status in ICC patients, which may facilitate identifying patients benefiting most from surgery and subsequent immunotherapy. Key points: • The combined (radiomics nomogram) model consisted of the radiomics model and clinical model (arterial phase diffuse hyperenhancement and AJCC 8th stage). • The radiomics nomogram showed better performance in predicting TLSs than independent radiomics or clinical models in ICC patients. • Preoperative CT radiomics nomogram achieved more accurate stratification for RFS of ICC patients than the postoperative pathologic TLSs status. Graphical

14 September 2023 in Hepatology International
Verified
Journal Article
Closed access
PDF file
JOJingzhong Ouyang
Jingzhong Ouyang
YYYi Yang
Yi Yang
YZYanzhao Zhou
Yanzhao Zhou
YYYeng Ye
Yeng Ye
ZWZhengzheng Wang
Zhengzheng Wang
ZJZhou Jinxue
Zhou Jinxue

15 May 2024 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
CYChao Yang
Chao Yang
HYHong-Cai Yang
Hong-Cai Yang
YLYin-Gen Luo
Yin-Gen Luo
FLFu-Tian Li
Fu-Tian Li
TCTian-Hao Cong
Tian-Hao Cong
XLXiao Li
Xiao Li

13 December 2024 in La radiologia medica
Verified
Journal Article
Closed access
PDF file
JOJingzhong Ouyang
Jingzhong Ouyang
YYYi Yang
Yi Yang
YXYing Xu
Ying Xu
ZWZhengzheng Wang
Zhengzheng Wang
YZYanzhao Zhou
Yanzhao Zhou
ZJZhou Jinxue
Zhou Jinxue

19 April 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
YXYing Xu
Ying Xu
YYYi Yang
Yi Yang
LLLu Li
Lu Li
AZAiping Zhou
Aiping Zhou
HZHongmei Zhang
Hongmei Zhang
XZXinming Zhao
Xinming Zhao
Purpose: We aimed to compare different radiological criteria in evaluating the early tumor response of patients with unresectable hepatocellular carcinoma (uHCC) treated with an anti-programmed cell death protein 1 (PD-1) antibody plus bevacizumab.Method: From October 2018 to January 2020, 58 patients [49 (84.5%) men, age = 55.2 ± 10.6 years] receiving both anti-PD-1 antibody and bevacizumab were retrospectively included. Pre- and the first posttreatment contrast-enhanced computed tomography (CE-CT) scans were performed in all patients. The Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), modified RECIST (mRECIST), Choi, and the revised Choi (rChoi) criteria were applied to evaluate tumor response. The endpoint event was defined as overall survival (OS).Results: Six (10.3%), 9 (15.5%), 30 (51.7%), and 12 (20.7%) patients were diagnosed as responders by RECIST 1.1, mRECIST, Choi, and rChoi, respectively. The RECIST 1.1 and mRECIST criteria failed to correlate the evaluation categories with OS (p = 0.130 and 0.253, respectively), while both Choi and rChoi significantly correlated with OS (p = 0.002 and 0.006, respectively). Among the four criteria, only those patients identified as responders by Choi (p = 0.0005) and rChoi (p = 0.005) showed significantly better OS than the non-responders. The cumulative 1- and 2-year OS rates by Choi were 93.3% and 79.8% in responders and 69.3% and 30.3% in non-responders, respectively; these rates were 100.0% and 100.0% in responders and 74.9% and 43.1% in non-responders by rChoi, respectively.Conclusions: The evaluation of early tumor response using Choi and rChoi instead of RECIST 1.1 and mRECIST significantly correlated with the OS of patients with uHCC treated with an anti-PD-1 antibody plus bevacizumab. Moreover, patients identified as responders by Choi and rChoi showed significantly better OS than the non-responders.

23 September 2023 in European Radiology
Verified
Journal Article
Closed access
PDF file
YXYing Xu
Ying Xu
YYYi Yang
Yi Yang
JOJingzhong Ouyang
Jingzhong Ouyang
YZYanzhao Zhou
Yanzhao Zhou
LLLu Li
Lu Li
HZHong Zhao
Hong Zhao